Activity Overview
This educational activity is an archive of the live presentation held on June 24, 2026.
Target Audience
This educational program is directed toward community-based medical oncologists, hematologic oncologists, hematologists, hematopathologists, nurse practitioners, physician assistants, nurses, pharmacists, and other health care professionals involved in the treatment of follicular lymphoma (FL).
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Apply guideline recommendations and practice-changing advances to treatment selection in relapsed/refractory FL
- Analyze evidence for current and emerging therapeutics in the context of sequencing in FL
- Assess data from ongoing studies that impact the evolving treatment paradigms in FL
Krish Patel, MD
Director, Lymphoma Research
Sarah Cannon Research Institute
Nashville, TN
Disclosures: Advisor, Consultant, Fee for Service Recipient: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, BMS/Celgene/Juno, Caribou Biosciences, Epizyme, Fate Therapeutics, Genentech, Kite (a Gilead company), Loxo/Lilly, MorphoSys, Pharmacyclics, Seagen, TG Therapeutics, Xencor; Speakers Bureau: AstraZeneca, BMS/Celgene, Kite (a Gilead company), TG Therapeutics; Grant/Research Funding (to institution): Aptevo Therapeutics, AstraZeneca, BMS, Celgene, Curis, Epizyme, Fate Therapeutics, Kite/Gilead, Loxo/Lilly, MEI Pharma, Nurix, Pfizer, Pharmacyclics, Roche/Genentech, Takeda, Trillium Therapeutics, Xencor
Girish Kunapareddy, MD
Assistant Professor of Clinical Medicine
Indiana University School of Medicine
Medical Director of Oncology Service Line
Medical Oncologist/Hematologist
Union Health
Terre Haute, IN
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Genentech, Novartis, Takeda; Grant/Research Support: BMS, Eisai, Geron, GSK, Guardant, Incyte, Natera, Pfizer
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login HereAccreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.
Physicians' Education Resource®, LLC (PER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Physicians' Education Resource®, LLC has approved this
application-based activity for 1.00 ACPE CE hours UAN # 0661-0000-26-011-H01-P.
Eligibility for credits requires full engagement with the enduring activity,
completion and submission of the learner NABP ID # and month and day of birth,
activity pre/post-session questions, and the post activity evaluation. This UAN
# expires November 13, 2026.
